Welcome to our dedicated page for Avantor SEC filings (Ticker: AVTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avantor, Inc. filings document operating results, financial condition and segment reporting for a life science tools company serving life sciences and advanced technology customers. Recent 8-K reports furnish quarterly and annual earnings releases, non-GAAP measures such as adjusted EBITDA and free cash flow, guidance references, and the realignment of reportable segments into VWR Distribution & Services and Bioscience & Medtech Products, including recast historical segment information.
The company’s proxy and current reports also disclose governance matters, director elections, board committee assignments, executive officer transitions, compensation arrangements and annual meeting materials. These filings frame Avantor’s public-company disclosures around its product and services portfolio, leadership structure and shareholder voting matters.
Avantor, Inc. executive Mary Blenn, EVP and Chief Operating Officer, reported equity awards received on February 19, 2026. She acquired stock options for 1,041,766 shares of common stock at an exercise price of $0.00 per option and a grant of 235,993 shares of common stock.
The filing notes that the restricted stock units vest in three equal annual installments beginning on February 19, 2027. The stock options also vest in three equal annual installments starting on the same date, aligning her compensation with long-term company performance.
Avantor, Inc. executive Steven W. Eck, SVP & Chief Accounting Officer, reported equity-based compensation and related tax withholding transactions. On February 19, 2026, he received a grant of 48,859 shares of common stock in the form of restricted stock units that vest in three equal annual installments beginning on February 19, 2027. He was also granted 43,230 stock options that vest on the same three-year schedule starting on that date. On February 20, 2026, 2,125 shares of common stock were withheld at $9.03 per share to cover tax obligations from RSU vesting, a tax-withholding disposition rather than an open-market sale. After these transactions, he directly held 101,802 shares of common stock and 43,230 stock options.
Avantor, Inc. reported that President and CEO Emmanuel Ligner received new equity awards under a compensation arrangement. On February 19, 2026, he was granted stock options for 1,903,847 shares at an exercise price of $0.00 per share and a separate award of 483,713 shares of common stock in the form of restricted stock units. The RSUs and options each vest in three equal annual installments beginning on February 19, 2027, aligning a significant portion of his compensation with the company’s long-term performance.
Avantor, Inc. president Corey Walker reported new equity awards and a related tax share withholding. On February 19, 2026, he acquired 161,237 shares of common stock as a restricted stock unit grant and 634,617 stock options, both vesting in three equal annual installments beginning on February 19, 2027.
On February 20, 2026, 4,963 common shares were disposed of through a tax-withholding transaction at $9.03 per share, with shares withheld by the issuer to cover RSU tax obligations, not an open-market sale. After these transactions, Walker directly held 387,545 common shares.
Avantor, Inc. executive Claudius Sokenu, EVP and Chief Legal & Compliance Officer, reported equity compensation changes. He received a grant of 80,618 shares of common stock as restricted stock units that vest in three equal annual installments beginning on February 19, 2027.
He was also granted 317,310 stock options, which vest on the same three-year schedule starting February 19, 2027. In a separate transaction, 2,919 shares of common stock were withheld at $9.03 per share to cover tax obligations upon RSU vesting, leaving him with 254,805 common shares held directly after that withholding.
Avantor EVP Benoit Gourdier reported new equity awards and related tax withholding. On February 19, 2026 he received 134,364 restricted stock units and 528,848 stock options, each vesting in three equal annual installments beginning February 19, 2027. On February 20, 2026, 4,160 common shares at $9.03 were withheld to cover taxes, leaving 365,888 common shares held directly.
Avantor, Inc. executive vice president and chief financial officer Jones R. Brent reported equity compensation changes and related tax withholding. He received a grant of 161,237 shares of common stock as restricted stock units and 634,617 stock options, both vesting in three equal annual installments beginning on February 19, 2027.
To cover tax withholding obligations from restricted stock unit vesting, 9,506 shares of common stock were withheld by Avantor as a tax-withholding disposition. After these transactions, Brent continued to hold a substantial number of Avantor shares directly.
Avantor director Gregory L. Summe, through a trust, reported an open-market purchase of 100,000 shares of common stock on February 12, 2026 at $9.40 per share. After this transaction, the trust held 400,000 shares indirectly attributed to him.
Separately, Summe also reported 58,111 shares of Avantor common stock held directly. The filing notes that he disclaims beneficial ownership of the trust’s shares except to the extent of his economic interest, meaning the trust is the primary holder of that indirect position.
Avantor reported weaker results for the fourth quarter and full year 2025 and announced a major segment realignment. Fourth-quarter net sales were $1.66 billion, down 1.4% year over year, with organic sales down 4.1%. Net income fell sharply to $52 million, while adjusted EBITDA was $252 million with a 15.2% margin and adjusted EPS of $0.22.
For full year 2025, net sales were $6.55 billion, down 3.4% (2.8% organic decline). The company posted a net loss of $530 million, compared with net income of $712 million in 2024, largely reflecting a $785 million goodwill impairment. Adjusted EBITDA was $1.07 billion with a 16.3% margin and adjusted EPS of $0.90. Operating cash flow remained solid at $624 million, generating free cash flow of $496 million and adjusted net leverage of 3.2x.
Laboratory Solutions full‑year net sales declined 4.6% to $4.40 billion and Bioscience Production declined 1.0% to $2.15 billion, with margins compressing in both. Avantor is executing a “Revival” program, including relaunching the VWR brand and supply chain and e‑commerce improvements, and will realign into two new segments—VWR Distribution & Services and Bioscience & Medtech Products—starting with the first quarter of 2026.
Avantor, Inc. is a global supplier of mission-critical products and services for biopharma and healthcare, education and government, and advanced technologies customers. It operates through Laboratory Solutions and Bioscience Production, combining its VWR distribution channel with proprietary brands like J.T. Baker, NuSil and Masterflex.
The company serves more than 300,000 customer locations in about 180 countries, with over 85% of net sales coming from recurring materials, equipment and services. Around 80% of 2025 transactions ran through its digital channels, supported by integrated ERP and e-commerce platforms.
Avantor is running a multi‑year cost transformation program, now targeting about $400 million in annual gross run‑rate savings by the end of 2027, alongside a refined operating model. Key risks include supply chain constraints and inflation, intense competition, reliance on key suppliers, extensive global regulatory and environmental requirements, cybersecurity and data privacy exposure, climate and sustainability pressures, and a significant debt load with related covenant limits.